Compare MBINM & BCTXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MBINM | BCTXL |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2017 | 2025 |
| Metric | MBINM | BCTXL |
|---|---|---|
| Price | $25.63 | $0.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.4K | 3.6K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.73 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.40 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.00 | $0.61 |
| 52 Week High | $25.96 | $1.40 |
| Indicator | MBINM | BCTXL |
|---|---|---|
| Relative Strength Index (RSI) | 56.30 | 45.72 |
| Support Level | $25.30 | $0.76 |
| Resistance Level | $25.77 | $1.21 |
| Average True Range (ATR) | 0.12 | 0.09 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 87.10 | 47.80 |
Merchants Bancorp is a United States-based bank holding company operating multiple lines of business focused on FHA multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. Its segments include Multi-family Mortgage Banking, which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing, which offers mortgage warehouse financing, commercial loans and deposit services; and the Banking segment, which generates maximum revenue and provides portfolio lending for multi-family and healthcare facility loans, residential mortgage banking, agricultural lending, SBA lending and community banking.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.